The FDA Grand Rounds is an educational presentation that is webcast monthly to highlight cutting-edge research underway across the Agency and its impact on protecting and advancing public health. Each session features an FDA scientist presenting on a key public health challenge and how FDA is applying science to its regulatory activities. The 45-minute educational presentation is followed by questions from the audience. You can also view the presentation under Past Grand Rounds following the live webcast. #FDAGrandRounds.
The next FDA Grand Rounds is scheduled for June 11, 2020. (Webcast only)
Thursday, June 11, 2020
12:00 p.m. - 1:00 p.m. EST
- Bernadette Dunham, D.V.M., Ph.D. Professorial Lecturer, Milken Institute School of Public Health, George Washington University, Advisor to the FDA One Health Initiative, Center for Veterinary Medicine, FDA.
- CAPT Brianna Skinner, D.V.M., M.P.H., DACLAM CAPT, USPHS, Senior Regulatory Veterinarian, Office of the Commissioner, Office of Counterterrorism and Emerging Threats, FDA.
About the Presentation:
The Food and Drug Administration (FDA) is responsible for protecting the public health by ensuring the safety, efficacy, and security of human and veterinary drugs, biological products, and medical devices; and by ensuring the safety of our nation's food supply, cosmetics, and products that emit radiation. There are many factors that pose risks or threaten public health. FDA’s efforts to improve health goes beyond recognizing disease transmission in an isolated lens of human health, but also acknowledges human-animal interactions and associated environmental factors such as socioeconomic status, behavior, and other social determinants. Addressing human and animal intersectoral factors that are both biological and environmental is a complex endeavor requiring a great deal of knowledge, skills, and resources from various disciplines. However, as health disciplines become progressively specialized, they also become more siloed. One Health is a concept that embraces a multisectoral and transdisciplinary approach to solving health problems by recognizing the interconnection between humans, animals, and their shared environment. Many global changes and activities associated with increased human-animal interactions are enabling disease transmission that become epidemics or pandemics that adversely impact public health. This presentation will explain the One Health Concept and the FDA One Health Initiative. It will also highlight the benefits of One Health and how FDA is operationalizing One Health actions Agency-wide.
What you’ll learn about FDA’s One Health Initiative:
- The mission and goals of FDA's One Health Initiative.
- Recent FDA One Health Initiative-related activities.
- Why a One Health approach to pandemics is the new norm.
- Artificial Intelligence for Regulatory Science Research
- Analysis of Per and Polyfluoroalkyl Substances (PFAS) in foods- Analytical method development, challenges and successes
- Modernization of Pharmaceutical Manufacturing through the Adoption of Advanced Technology
- Detection of Transmissible Spongiform Encephalopathy Agents in Biological Products Using Protein Aggregation Assays
- Quality Control: Stopping infections before they happen through safer endoscope reprocessing
- Vet-LIRN – How FDA’s Network of Veterinary Diagnostic Laboratories advance animal food safety and public health by conducting outbreak investigations and monitoring resistance in animal pathogens
- Technical and Logistical Considerations for Examining FDA-Regulated Products at International Mail Facilities using Handheld and Field-Portable Analytical Devices
- Jerky Pet Treats and illness in dogs: a collaborative approach to investigating a mysterious outbreak
- Decomposition of Seafood Products by Mass Spectrometry with Sensory-Driven Predictive Modeling
- The Science to Inform a Tobacco Product Standard for the Level of Nicotine in Combusted Cigarettes
- Bisphenol A: Toxicology and Pharmacokenetic Data to Inform Ongoing Safety Assessments
- How Simulation Can Transform Regulatory Pathways
- FDA's Predictive Toxicology Roadmap: Implications and Opportunities for Stakeholders
- Are Stem Cells Ready for Prime Time? A Look at FDA Research Advances in Regenerative Medicine
- Ethnicity- and Gender-Related Differences in Alzheimer's Disease
- Assessing the Safety and Effectiveness of New and Emerging Therapeutic Ultrasound Technologies
- Developing a Mechanistic Model-Based Approach to Assess Cardiac Safety of New Drugs
- Genome Trakr: How a Large Network of Sequencing Laboratories is Transforming Food Safety and Public Health
- Serious and Actionable Risks, Plus Disclosure: investigating an Alternative Approach for Presenting Risk Information in Prescription Drug TV Ads
- Vaccine adjuvants: New ways to evaluate their safety and effectiveness
- Developing Regulatory Methods for Characterizing Nanomaterials in FDA-Regulated Products
- The Host Response to Whooping Cough Infection and Vaccination [Archived]
- Antibiotic resistance surveillance in the age of genomics: New answers to old questions [Archived]
- FDA Research into 3D Printing of its Regulated Products [Archived]
- Rapid Screening of Dietary Supplements for Undeclared Ingredients [Archived]
- Metabolomics and Proteomics Biomarkers: Discovery and Validation in Toxicity Studies [Archived]